Adding the results presented here to previous evidence, early recognition of high levels of cystatin C combined with reduction of modifiable cardiovascular risk factors seems to offer great potential to lower the impact of socioeconomic inequalities on Cystatin C as a marker for renal dysfunction on the subclinical level. The gene discussed is CST3; the disease is Abnormal renal physiology.